The Influence and Mechanism of GLP-1 RAs in Ameliorating Ischemic Cardiomyopathy Myocardial ischemia and reperfusion injury play a pivotal role in the onset and progression of myocardial infarction and heart failure
Comparisons With Other Diabetes Therapies Putting GLP1s in context with other antidiabetic agents offers additional insights: Thiazolidinediones (TZDs) are associated with increased fracture risk, especially in women SGLT2 inhibitors have raised concerns in some trials, particularly canagliflozin DPP-4 inhibitors appear largely neutral regarding skeletal effects Against this backdrop, GLP1s may have a neutral or possibly safer profile, though the data are not conclusive
The slight vacuum created is negligible and won't prevent accurate dosing
Common Side Effects (Both Peptides) Mild injection site irritation (redness, minor swelling) Headache (typically early in treatment) Temporary flushing or warmth after injection Mild changes in appetite When Medical Evaluation Is Essential Peptide therapy should always be preceded by: Comprehensive symptom assessment Medical and medication history review Baseline laboratory testing (IGF-1, metabolic panel, hormonal markers) Evaluation for contraindications (active malignancies, certain pituitary conditions) Ongoing monitoring includes periodic IGF-1 testing, symptom tracking, and dosage adjustments based on clinical response